Blessing for the Bleeder: Bevacizumab in Hereditary Hemorrhagic Telangiectasia
暂无分享,去创建一个
[1] J. Saurin,et al. Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output. , 2012, JAMA.
[2] C. Freter,et al. Iron deficiency anemia related to hereditary hemorrhagic telangiectasia: response to treatment with bevacizumab. , 2012, The American journal of the medical sciences.
[3] Z. Ge,et al. Efficacy of thalidomide for refractory gastrointestinal bleeding from vascular malformation. , 2011, Gastroenterology.
[4] N. Choong,et al. Long-term therapy with bevacizumab in hereditary hemorrhagic telangiectasia. , 2011, The New England journal of medicine.
[5] S. Dheyauldeen,et al. Anti-VEGF with 3-week intervals is effective on anemia in a patient with severe hereditary hemorrhagic telangiectasia , 2010, Annals of Hematology.
[6] J. Holter,et al. Bevacizumab in hereditary hemorrhagic telangiectasia. , 2009, The New England journal of medicine.
[7] S. Oosting,et al. More on bevacizumab in hereditary hemorrhagic telangiectasia. , 2009, The New England journal of medicine.
[8] L. Adams,et al. Bevacizumab reverses need for liver transplantation in hereditary hemorrhagic telangiectasia , 2008, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[9] L. David,et al. Identification of BMP9 and BMP10 as functional activators of the orphan activin receptor-like kinase 1 (ALK1) in endothelial cells. , 2007, Blood.
[10] W. Fischbach,et al. Dramatic improvement in hereditary hemorrhagic telangiectasia after treatment with the vascular endothelial growth factor (VEGF) antagonist bevacizumab , 2006, Annals of Hematology.
[11] H. Blau,et al. VEGF gene delivery to myocardium: deleterious effects of unregulated expression. , 2000, Circulation.
[12] A. Guttmacher,et al. Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). , 2000, American journal of medical genetics.
[13] D. W. Johnson,et al. Mutations in the activin receptor–like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2 , 1996, Nature Genetics.
[14] K. Hörmann,et al. Patients with hereditary hemorrhagic telangiectasia have increased plasma levels of vascular endothelial growth factor and transforming growth factor-beta1 as well as high ALK1 tissue expression. , 2005, Haematologica.
[15] D. W. Johnson,et al. Endoglin, a TGF-β binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1 , 1994, Nature Genetics.
[16] H. Uchino,et al. DEPARTMENT OF INTERNAL MEDICINE , 1966 .